Go to deals
Healthcare

Bellefleur has been acquired by Domidep

Belgian nursing home Bellefleur has been sold to Domidep, one of France’s largest private nursing home operators.

Headquartered in Aubange, Belgium, Bellefleur owns and operates a state-of-the-art nursing home in the Luxembourg province. After the nursing home’s refurbishment and extension in 2022, Bellefleur operates 91 accredited beds, with a total capacity for 99 beds. Through its strategic location, a limited competitive landscape in the region and efficient management, Bellefleur has been able to achieve an occupancy rate of around 100% for long-term stays since 2022.

Founded in 1989, Domidep is a leading player in the healthcare sector, operating mainly medicalized nursing homes. On the strength of its roots and experience in France, with almost 120 establishments at the end of 2022 accommodating 7,700 residents, Domidep is now also expanding internationally. The company is already present in Germany and Belgium, with over 35 establishments for almost 2,900 residents.

Oaklins’ team in Belgium acted as the exclusive M&A sell-side advisor to Bellefleur in this transaction.

Parties

Talk to the deal team

Thomas Roelens

Managing Director
Brussels, Belgium
Oaklins KBC Securities

Jérôme Heinrich

Senior Associate
Brussels, Belgium
Oaklins KBC Securities

Related deals

Medicija has acquired Saulės Šeimos Medicinos Centras
Healthcare

Medicija has acquired Saulės Šeimos Medicinos Centras

Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.

Learn more
Quimpharma has completed the divestiture of a product portfolio to Megalabs
Healthcare

Quimpharma has completed the divestiture of a product portfolio to Megalabs

Quimpharma has completed the divestiture of a product portfolio to Megalabs México.

Learn more
IXICO has completed a fundraising
Healthcare

IXICO has completed a fundraising

IXICO plc, a specialist in AI-driven neuroimaging analytics, has completed a US$13.5 million gross capital raise. The funds will be used to support the company’s tech bio strategy, which will see IXICO partner its platform to maximize its potential.

Learn more